Press

 Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the completion of the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to Filament’s Metro Vancouver research and development facility. The import was authorized by the Gabonese government under the Nagoya Protocol, an international agreement which ensures sharing of the benefits arising from the utilization of genetic resources in a fair and equitable way, and the Gabonese Convention on Biological Diversity. The iboga root will undergo analysis at Filament’s facility, and be transformed into total alkaloid iboga extract, in partnership with…

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST. Interested participants are invited to register in advance by clicking here. Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study was led by Professor Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the…

Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), GMP-grade psilocybin, along with natural health product formulations, is pleased to announce the completion of its harvest of Psilocybe cubensis earmarked for export to Australia. This milestone builds off the previously announced commitment to supply both its GMP medical-grade psilocybin extract and MDMA to Mind Medicine Australia in advance of the historic rescheduling of these substances to be enacted on July 1, 2023….

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announces that a complaint was filed on May 1, 2023 in the United States District Court for the Southern District of Florida by GBB Drink Lab, Inc. (“GBB”) against FSD Pharma and its subsidiary, FSD Biosciences, Inc. (collectively, “FSD”). A copy of this complaint was delivered to FSD Pharma on May 9, 2023. The complaint claims that FSD breached a mutual nondisclosure agreement and misappropriation…

Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details activities of its psychedelic therapies subsidiary company, called Psychennex. A Media Snippet accompanying this announcement is available by clicking on the link : Incannex Contact Information: Incannex Healthcare LimitedMr Joel LathamManaging Director and Chief Executive Officer+61 409 840 786joel@incannex.com.au Investor Relations Contact – United StatesAlyssa FactorEdison Group+1 (860) 573 9637afactor@edisongroup.com